Skip to main content
SpringerLink
Log in

Systemische Therapie des hepatozellulären Karzinoms

Stadienadaptierte Strategie

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Der Multikinaseinhibitor Sorafenib ist die einzige zugelassene, systemisch wirksame Substanz bei fortgeschrittenem hepatozellulärem Karzinom. Neue molekulare Therapien sind in der klinischen Entwicklung, bisher aber mit meist negativen Ergebnissen. Es gilt nun, prognostische und prädiktive Faktoren für eine personalisierte Therapie zu identifizieren.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

    Article  CAS  PubMed  Google Scholar 

  2. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012. International Agency for Research on Cancer, World Health Organisation, Lyon, Frankreich. 2014. http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx. Accessed 17 Jun 2014.

  3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.

  4. Bruix J et al. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, AWMF Registrierungsnummer: 032-053OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html.

  6. Abou-Alfa GK et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.

    Article  CAS  PubMed  Google Scholar 

  7. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  8. Bolondi L et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Gastrointestinal Cancers Symposium. 2008. Abstr 129.

    Google Scholar 

  9. Bruix J et al. Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials. J Clin Oncol. 2009;27(Suppl 15):Abstr 4580.

    Google Scholar 

  10. Craxi A et al. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: a sub-analysis from the SHARP trial. J Clin Oncol. 2008;26(Suppl 15).Abstr 15591.

    Google Scholar 

  11. Galle P et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. J Hepatol. 2008;48(Suppl 2):Abstr 994.

    Google Scholar 

  12. Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  13. Ren Z et al. A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. J Clin Oncol. 2012;30(Suppl 15):Abstr 4008.

    Google Scholar 

  14. Lencioni R et al. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64(8):1034–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Lencioni R et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular cinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012;66(7):675–83.

    Article  CAS  PubMed  Google Scholar 

  16. Lencioni R et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):17.

    Article  Google Scholar 

  17. Marrero JA et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sortreated patients (pts): Clinical findings in pts with liver dysfunction. J Clin Oncol. 2013;31(Suppl):Abstr 4126).

    Google Scholar 

  18. Iavarone M et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54(6):2055–63.

    Article  CAS  PubMed  Google Scholar 

  19. Cheng AL et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75.

    Article  CAS  PubMed  Google Scholar 

  20. Bruix J et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of sharp trial based on Barcelona Clinic Liver Cancer (BCLC) stage. J Hepatol. 2009;50(Suppl 1):S28–S29.

    Article  Google Scholar 

  21. Faivre S1 et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009;10(8):794–800.

    Article  CAS  PubMed  Google Scholar 

  22. Llovet JM et al. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. J Clin Oncol. 2013;31(28):3509–16.

    Article  CAS  PubMed  Google Scholar 

  23. Johnson PJ et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013; 31(28):3517–24.

    Article  CAS  PubMed  Google Scholar 

  24. Philip PA et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–63.

    Article  CAS  PubMed  Google Scholar 

  25. Thomas MB et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110(5):1059–67.

    Article  CAS  PubMed  Google Scholar 

  26. Thomas MB et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843–50.

    Article  CAS  PubMed  Google Scholar 

  27. Ramanathan RK et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–83.

    Article  CAS  PubMed  Google Scholar 

  28. Zhu AX et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581–9.

    Article  CAS  PubMed  Google Scholar 

  29. Zhu AX et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). Ann Oncol. 2012;23(Suppl 9):Abstr LBA2.

    Google Scholar 

  30. O’Neil BH et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29(17):2350–6.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Villanueva A et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Zhu AX et al. EVOLVE-1: Phase 3 Study of Everolimus for Advanced HCC that Progressed During or After Sorafenib. J Clin Oncol. 2014;32(Suppl 3):Abstr 172.

    Google Scholar 

  33. Birchmeier C et al. Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. Int Rev Cytol. 1995;120:221–66.

    Article  Google Scholar 

  34. Kaposi-Novak P et al. Met-regulated expression signature defines a sub-set of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116(6):1582–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Ueki T et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25(3):619–23.

    Article  CAS  PubMed  Google Scholar 

  36. Verslype C et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012; 30(Suppl):Abstr 4007.

    Google Scholar 

  37. Santoro A et al. Tivantinib for second-line treatment of advanced hepato-cellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.

    Article  CAS  PubMed  Google Scholar 

  38. Bruix J et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49(16):3412–9.

    Article  CAS  PubMed  Google Scholar 

  39. Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.

    Article  CAS  PubMed  Google Scholar 

  40. Cainap C, Qin S, Huang W et al. Phase 3 trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2013;31(Suppl 4):Abstr 249.

    Google Scholar 

  41. Velandia-Carrillo C et al. Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report. BMC Endocr Disord. 2014;14(1):26.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Nora Schweitzer

  2. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Arndt Vogel

Authors
  1. Nora Schweitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arndt Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arndt Vogel.

Additional information

Interessenkonflikt

Prof. Dr. Arndt Vogel gibt Zusammenarbeit in HCC-Studien mit und Beratungs- sowie Vortragstätigkeit für Bayer und Lilly an. Dr. Nora Schweitzer erklärt, keine Interessenkonflikte zu haben.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheits bildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schweitzer, N., Vogel, A. Systemische Therapie des hepatozellulären Karzinoms. Im Focus Onkologie 17, 40–49 (2014). https://doi.org/10.1007/s15015-014-0006-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-0006-8

Search

Navigation